SHARP1, a basic helix-loop-helix transcription factor, is expressed in many cell types; however, the mechanisms by which it regulates cellular differentiation remain largely unknown. Here, we show that SHARP1 negatively regulates adipogenesis. Although expression of the early marker CCAAT/enhancer binding protein b (C/EBPb) is not altered, its crucial downstream targets C/EBPa and peroxisome proliferator-activated receptor c (PPARc) are downregulated by SHARP1. Protein interaction studies confirm that SHARP1 interacts with and inhibits the transcriptional activity of both C/EBPb and C/EBPa, and enhances the association of C/EBPb with histone deacetylase 1 (HDAC1). Consistently, in SHARP1-expressing cells, HDAC1 and the histone methyltransferase G9a are retained at the C/EBP regulatory sites on the C/EBPa and PPARc2 promoters during differentiation, resulting in inhibition of their expression. Interestingly, treatment with troglitazone results in displacement of HDAC1 and G9a, and rescues the differentiation defect of SHARP1-overexpressing cells. Our data indicate that SHARP1 inhibits adipogenesis through the regulation of C/EBP activity, which is essential for PPARc-ligand-dependent displacement of co-repressors from adipogenic promoters.
INTRODUCTION
Transcriptional regulation of adipogenic differentiation is a tightly controlled process that is regulated by members of two protein families: the CCAAT/enhancer binding proteins (C/EBPs) and the peroxisome proliferator-activated receptors (PPARs; Rosen et al, 2000; Farmer, 2006; Rosen & MacDougald, 2006) . Following exposure of preadipocytes to differentiation-inducing hormones, C/EBPb and C/EBPd are rapidly and transiently expressed, and transcriptionally regulate the expression of C/EBPa and PPARg, which, in turn, regulate the expression of many genes required for terminal differentiation (Wu et al, 1996 (Wu et al, , 1999 . Several effectors modulate the expression or activity of C/EBPs and PPARg and thereby affect adipogenic differentiation. This includes transcription factors, cell-cycle regulators and signalling pathways such as Wnt, Notch, Hypoxia and Hedgehog. In addition, recent evidence indicates that histone modifiers result in epigenetic alterations that allows the formation of transcriptionally competent chromatin during differentiation (Farmer, 2006; Rosen & MacDougald, 2006) . SHARP1/DEC2 (Rossner et al, 1997; Fujimoto et al, 2001 ) is a member of the transcriptional repressor subfamily of basic helixloop-helix (bHLH) transcription factors (Sun et al, 2007a) that is expressed in various embryonic and adult tissues (Azmi & Taneja, 2002; Azmi et al, 2003) . We have shown previously that overexpression of SHARP1 results in inhibition of myogenic differentiation (Azmi et al, 2004) . Consistent with these findings, SHARP1 was found to be overexpressed in inclusion body myositis mesangioblasts that fail to differentiate into skeletal muscle (Morosetti et al, 2006) . However, little is known about the function of SHARP1 in differentiation of other cell types and the mechanisms underlying its function as a transcriptional repressor remain to be fully defined.
Here, we show by using both gain-of-function and loss-offunction approaches that SHARP1 inhibits adipogenesis. SHARP1 interacts with C/EBPb and C/EBPa and inhibits their activity. The interaction with C/EBPb is essential for SHARP1-mediated inhibition of differentiation. In the presence of SHARP1, the association of C/EBPb with histone deacetylase 1 (HDAC1) is 
RESULTS AND DISCUSSION Expression of SHARP1 is modulated during adipogenesis
We have shown previously that SHARP1 is expressed in several embryonic and adult tissues (Azmi & Taneja, 2002; Azmi et al, 2003) . We characterized its pattern of expression in adipose tissue; SHARP1 RNA was detected in both white and brown adipose tissue of adult mice (Fig 1A) , and its expression was elevated in white adipose tissue of mice fed with a high-fat diet ( Fig 1B) . SHARP1 RNA levels were transiently downregulated during differentiation in 3T3L1 and 10T1/2 cells, coincident with an increase in C/EBPb, and upregulated again during terminal differentiation (Fig 1C,D) .
SHARP1 inhibits adipogenic differentiation
To determine whether SHARP1 overexpression in adipocyte precursor cells modulates differentiation, 3T3L1 cells were infected with retrovirus expressing SHARP1 (pBabe-SHARP1) or with the vector alone (pBabe) as a control. Cells overexpressing SHARP1 showed a decrease in the number of differentiated adipocytes compared with vector-infected cells as seen by OilRed-O (ORO) staining (Fig 2A,B) . To investigate the mechanisms underlying this inhibitory effect, we examined the expression of early and late adipogenic markers during differentiation by using Western blot analysis. The expression of C/EBPb was not altered; however, its downstream transcriptional targets C/EBPa and PPARg2 (Christy et al, 1991; Clarke et al, 1997) were downregulated in pBabe-SHARP1 cells (Fig 2C) , suggesting that SHARP1 inhibits adipogenesis through C/EBPb. In addition, adipocyte fatty-acid binding protein 2 (AP2), a target of both PPARg and C/EBPa, was also reduced in SHARP1-expressing cells.
To examine whether inhibition of late adipogenic markers was SHARP1 inhibits adipogenesis N.T. Gulbagci et al caused by altered transcriptional regulation, we analysed C/EBPa, PPARg2 and AP2 messenger RNA (mRNA) levels. Transcripts of these late differentiation markers, as well as glucose transporter 4 (GLUT4) and sterol regulatory element binding protein 1c (SREBP1c), were lower in SHARP1-overexpressing cells. By contrast, pre-adipocyte factor 1 (PREF1), which is downregulated during differentiation, was regulated normally ( Fig 2D) . As C/EBPa has a crucial function in adipogenesis and is a transcriptional target of C/EBPb, we examined whether re-introducing C/EBPa could rescue SHARP1-mediated block of adipogenesis. Reexpression of C/EBPa rescued the inhibition of differentiation in SHARP1-overexpressing cells as seen by ORO staining (Fig 2E) , indicating that repression of C/EBPa is important for SHARP1-mediated inhibition of adipogenesis. Consistent with these studies, SHARP1 À/À mouse embryonic fibroblast (MEF) cells showed increased differentiation relative to wild-type cells, confirming that endogenous SHARP1 regulates adipogenesis ( Fig 3A) . Furthermore, the expression of C/EBPb was unaltered, whereas CEBPa, PPARg2 and AP2 levels were higher in mutant MEFs compared with wild-type controls (Fig 3B) .
SHARP1 inhibits the activity of C/EBP
To examine the mechanisms underlying reduced expression of C/EBPa and PPARg2, we analysed whether SHARP1 modulates the localization of C/EBPb, DNA binding or transcriptional activity. No alteration in the localization of C/EBPb or DNA binding was evident from gel-shift assays or by chromatin immunoprecipitation (ChIP) assays ( Supplementary Fig 1A-C  online) . We then examined the activity of C/EBPb in the presence of SHARP1 by using reporter assays ( Supplementary Fig 1D  online) . C/EBPb-activated reporter activity was downregulated by SHARP1 in a dose-dependent manner. Furthermore, SHARP1 also inhibited C/EBPa-induced PPARg promoter activity, indicating that SHARP1 regulates the transcriptional activity of both C/EBPb and C/EBPa.
SHARP1 retains HDAC1 and G9a on adipogenic promoters
To examine the mechanisms underlying reduced expression of C/EBPa and PPARg2, ChIP assays were performed. During differentiation, an increase in H3K9acK14ac-a mark of transcriptionally active regions-was seen at the C/EBPa promoter ( Fig 4A) in a region encompassing the C/EBP site in control cells but not in SHARP1-overexpressing cells. H3K9acK14ac levels were also lower at the PPARg2 promoter in SHARP1-overexpressing cells (Fig 4B) . Reduced acetylation could be due to sustained recruitment of HDACs, reduced recruitment of coactivators or changes in histone H3 methylation (K9) associated with transcriptional repression. Therefore, we analysed HDAC1, the histone methyltransferase G9a that methylates K9 and K27 of histone H3, as well as the levels of CREB binding protein (CBP). HDAC1 and G9a levels were downregulated during differentiation of control cells (Yoo et al, 2006) , whereas SHARP1-overexpressing cells retained HDAC1 and G9a on both promoters. Consistent with sustained G9a, an increase in H3K9me2 was apparent in SHARP1-overexpressing cells, with no change in CBP recruitment. These results indicate that reduced expression of C/EBPa and PPARg2 is probably due to sustained levels of HDAC1 and/or G9a rather than the loss of activity of histone acetyl transferase (HAT).
SHARP1 retains co-repressors on adipogenic promoters
As SHARP1 prevents dissociation of HDAC1 and G9a on the C/EBPa and PPARg2 promoters in a region that contains the C/EBP SHARP1 inhibits adipogenesis N.T. Gulbagci et al regulatory site, we tested whether SHARP1 interacts with C/EBPs. NIH3T3 and 3T3L1 cells were transfected with full-length Myc-SHARP1 or its deletion mutants SHARP1DC and SHARP1DbHLH, along with C/EBPb. Full-length SHARP1 interacted with C/EBPb, whereas no interaction was seen with SHARP1DC or SHARP1DbHLH in NIH3T3 cells (Fig 5A, left  panel) , or 3T3L1 cells ( Fig 5A, right panel; Supplementary Fig 2  online) . Similarly, full-length SHARP1 interacted with C/EBPa in NIH3T3 and 3T3L1 cells (Fig 5B, left and right panels, respectively). Both C/EBPb and C/EBPa showed a direct interaction with SHARP1, as seen by glutathione S-transferase (GST) pulldown assays (Fig 5C) . Previous studies have shown an interaction between C/EBPb and HDAC1 (Wiper-Bergeron et al, 2003) . As SHARP1 interacts with CEBPb, we investigated the effect of SHARP1 on the CEBPb-HDAC1 complex. Interestingly, only fulllength SHARP1 increased the association of C/EBPb with HDAC1 (Fig 5D) , indicating that SHARP1 might inhibit the transcriptional activity of C/EBP through enhanced co-repressor recruitment. To test whether interaction with C/EBPb is essential for the inhibition of adipogenesis, SHARP1, SHARP1DC and SHARP1DbHLH were expressed in 3T3L1 cells. In contrast to full-length SHARP1, neither mutant inhibited adipogenic differentiation (Fig 6A) or expression of C/EBPa and PPARg (Fig 6B) , indicating that the interaction of SHARP1 with C/EBPb is essential for SHARP1-mediated inhibition of adipogenesis. In addition to regulating the expression of C/EBPa and PPARg2, C/EBPb also regulates PPARg ligand production (Hamm et al, 2001) , which is essential for the removal of HDAC1 from the C/EBPa promoter (Zuo et al, 2006 ). Therefore, we tested the effect of troglitazone on SHARP1-mediated inhibition of adipogenesis. Interestingly, troglitazone rescued the differentiation defect in cells overexpressing SHARP1, and the expression of PPARg2 and C/EBPa was also restored (Fig 6C,D) . Furthermore, during differentiation, HDAC1, G9a and H3K9me2 levels were reduced on the C/EBPa promoter by SHARP1 inhibits adipogenesis N.T. Gulbagci et al treatment with troglitazone (Fig 6E) , indicating that reduced PPARg ligand production underlies the sustained presence of HDAC1 and G9a, and inhibition of adipogenesis. Taken together, our results show a new function for SHARP1 in regulating the transition from preadipocytes to adipocytes through regulation of C/EBP activity. The activity of C/EBPb is essential for the expression of C/EBPa and PPARg2. In addition, the activity of C/EBPb and SREBP1c has been implicated in PPARg ligand production (Kim et al, 1998; Hamm et al, 2001) , which is required to dislodge HDAC1 from the C/EBPa promoter (Zuo et al, 2006) .
The downregulation of SREBP1c expression in SHARP1-overexpressing cells might contribute to the retention of co-repressors on adipogenic promoters. However, SHARP1 mutants that fail to interact with C/EBPb do not inhibit differentiation. Furthermore, SHARP1 increases the association of CEBPb with HDAC1. These results suggest that SHARP1 enhances and might stabilize the interaction of co-repressors with C/EBPb, resulting in the sustained presence of HDAC1 and G9a on the C/EBP regulatory sites in adipogenic promoters. The failure to dissociate co-repressors probably results in epigenetic changes that lead to the suppression SHARP1 inhibits adipogenesis N.T. Gulbagci et al of C/EBPa and PPARg2 expression and adipogenic differentiation. In addition to regulating early stages of the adipogenic programme through C/EBPb, the upregulation of SHARP1 during terminal differentiation might be important to curtail the activity of C/EBPa and thereby regulate late stages of differentiation. Given its effect on adipogenesis, aberrant SHARP1 function might be associated with obesity and obesity-related diseases.
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METHODS
Mice. Wild-type mice (5 weeks old) were fed with normal or a high-fat diet (Research Diets, New Brunswick, NJ, USA) for 5 months. RNA was isolated from fat pads and analysed for the expression of SHARP1. SHARP1 À/À mice were recently described (Rossner et al, 2008) . All animal protocols followed institutional guidelines. Cell culture. Wild-type and SHARP1 À/À MEF cells were generated from littermate embryos as described previously (Sun et al, 2007b) . 3T3L1, 10T1/2, Phoenix cells and MEFs were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. NIH3T3 cells were cultured in Dulbecco's modified Eagle's medium with 10% bovine serum. Plasmid constructs. pCS2-Myc-SHARP1 (amino acids 1-410) and GST-SHARP1 have been described previously (Azmi et al, 2003) . Deletion mutants containing the bHLH domain of SHARP1 (SHARP1DC; amino acids 1-112), or the carboxy-terminal region (SHARP1DbHLH; amino acids 112-410) were cloned by PCR into pCS2 and pBabe-puro vectors. Primers used for amplification are provided in Supplementary Table I Retroviral infection and adipogenic differentiation. 3T3L1 cells were infected with viral supernatant in the presence of 8 mg/ml polybrene, and selected with 4 mg/ml puromycin. For rescue experiments, SHARP1-expressing cells were reinfected with pMCSV-C/EBPa, and selected with 100 mg/ml hygromycin. Differentiation of 3T3L1 and MEFs was induced with 3-isobutyl-1-methylxanthine (0.5 mM), insulin (1 mg/ml) and dexamethasone (250 mM) for 2 days, replaced with a medium containing 1 mg/ml insulin for 2 days, followed by growth medium. Troglitazone (5 mM) was added on the first 2 days of differentiation. Differentiated cells were fixed and stained with 0.5% ORO. Co-immunoprecipitation and GST pull-down assays. Co-immunoprecipitation and GST assays were carried out as described previously (Azmi et al, 2004) . For co-immunoprecipitation assays, NIH3T3 and 3T3L1 cells were transfected using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) with Myc-SHARP1 constructs, Flag-C/EBPb, HA-C/EBPa and Flag-HDAC1 as indicated. Cell lysates were prepared using radioimmunoprecipitation assay buffer, and immunoprecipitated and immunoblotted with appropriate antibodies as described in the figure legends. For GST assays, 5 mg of GST-SHARP1 or GST protein was incubated with 5 ml of in vitro translated 35 S-methionine-labelled C/EBPb or C/EBPa protein. GST beads were washed and run on SDS-PAGE gels. Electro mobility shift assay. Nuclear extracts (10 mg) and poly dI-dC (25 ng/ml) were incubated with 32 P-labelled doublestranded oligonucleotides containing the C/EBP consensus element 5 0 -TGCAGATTGCGCAATCTGCA-3 0 . For supershift assays, 0.2 mg of antibody was preincubated with nuclear lysate before the addition of probe. Samples were run on 5% polyacrylamide gels and exposed for autoradiography. ChIP. Assays were performed using the ChIP assay kit (Millipore, Billerica, MA, USA) as described previously (Azmi et al, 2003) . Here, 2 mg C/EBPb, CBP, HDAC1 (Santa Cruz, Santa Cruz, CA, USA), acetyl-H3 (K9K14) and dimethyl-H3 (K9; Upstate) and 10 mg G9a (Nishio & Walsh, 2004) antibodies were used for immunoprecipitation. Primers for amplification of C/EBPa, PPARg2 and b-actin promoters are provided in Supplementary  Table II online. Reverse transcription-PCR. RNA isolated with Trizol (Invitrogen) was reverse transcribed with AMV reverse transcriptase (Promega, Madison, WI, USA). The cDNA was amplified with primers specific to SHARP1, C/EBPa, PPARg, GLUT4, AP2, SREBP1c, PREF1 and 36B4. Primer sequences are provided in Supplementary Table III online. Quantitative PCR was carried out as described previously (Sun et al, 2007c) . Primer sequences are provided in Supplementary Table IV online. Supplementary information is available at EMBO reports online (http://www.emboreports.org).
